Side Effects w/ Acalabrutinib vs Ibrutinib for Chronic Lymphocytic Leukemia (CLL) - Dr. John Seymour

A clinical trial directly comparing acalabrutinib to ibrutinib used a novel methodology incorporating adverse event (side effect) duration and severity to calculate adverse event burden. It further confirms that acalabrutinib is better tolerated compared with ibrutinib for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Dr. John Seymour from Peter MacCallum Cancer Centre and colleagues presented the results of a phase 3 head-to-head trial of acalabrutinib versus ibrutinib at the American Society of Hematology (ASH) Annual Meeting in December 2022.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society